Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Colon cancer
At Hospital/Institution:  Presbyterian - St. Luke's Medical Center
Results 1-25 of 198 for your search:
Start Over
Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CALGB 80702, NCI-2011-02050, CALGB/SWOG 80702, CALGB-SWOG C80702, CDR0000675693, NCT01150045
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BT-CL-PGG-CRC1031, NCI-2011-00967, NCT01309126
Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: S0820, NCI-2012-02067, SWOG-S0820, NCT01349881
Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-102, NCI-2012-00575, NCT01483027
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: CPP-FAP-310, NCI-2013-01805, NCT01483144
The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy
Phase: Phase III
Type: Diagnostic
Age: 50 to 75
Trial IDs: CB-17-01/06, NCI-2014-00316, 2012-003983-32, NCT01694966
A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 2012-PT023, NCI-2013-00997, NCT01767857
Dapsone Gel, 5% in Reducing Rash in Patients with Metastatic Colorectal Cancer or Head and Neck Cancer Undergoing Chemotherapy with Cetuximab
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 13-012, NCI-2013-01729, NCT01931150
Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.52, NCI-2014-02486, 2012-000095-42, NCT02149108
Surgery or Non-surgical Management in Treating Patients with Intra-abdominal Cancer and Bowel Obstruction
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: S1316, NCI-2014-01497, SWOG/S1316, NCT02270450
Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: E-101:PH3:2012:004, NCI-2014-00786, NCT01297959
Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 85
Trial IDs: Neogenix 0901, NCI-2012-01393, NCT01040000
Hydroxychloroquine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 07210, NCI-2010-02018, NCT01206530
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2109, NCI-2012-00874, 2011-002578-21, NCT01449058
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2110, NCI-2012-00964, 2011-005875-17, NCT01543698
Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-130-02, NCI-2013-01786, NCT01605318
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552
Capecitabine and Ziv-Aflibercept in Treating Patients with Refractory Solid Tumors or Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: Pro00037688, NCI-2013-00472, NCT01661972
Iodine I 124 NM404 in Patients with Advanced Solid Malignancies
Phase: Phase II, Phase I
Type: Diagnostic
Age: 18 and over
Trial IDs: CO12901, NCI-2012-01953, 2012-0230-CP009, NCT01662284
A Phase 1/2 Study to Evaluate MEDI4736
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CD-ON-MEDI4736-1108, NCI-2012-02062, NCT01693562
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLGX818X2103, NCI-2013-02457, 2012-002138-35, NCT01719380
Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: VAR0090, NCI-2012-02988, 25597, NCT01769222
Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 201404101, NCI-2013-00650, NCT01790035
Start Over